TABLE 1.
Demographics and clinical characteristics of non‐hospitalized COVID‐19 patients in Wuhan
| No. (%) | ||||
|---|---|---|---|---|
| Characteristic | Total | Pneumonia | Nonpneumonia | P value |
| No. of patients | 153 | 96 (62.7) | 57 (37.3) | N.A. |
| Age, mean [range], years | 44.9 [18‐79] | 44.2 [18‐79] | 42.3 [28‐69] | 1 |
| Male | 56 (36.6) | 40 (41.7) | 16 (28.1) | .11 |
| Fever | 80 (52.3) | 77 (80.2) | 3 (5.4) | 5.04 × 10−21 |
| Dry cough | 77 (50.3) | 66 (68.8) | 11 (19.3) | 2.37 × 10−9 |
| Shortness of breath | 36 (23.5) | 35 (36.5) | 1 (1.8) | 9.78 × 10−8 |
| CT findings * | 116 (75.8) | 96 (100) | 20 (35.1) | 2.82 × 10−21 |
| Anorexia | 17 (11.1) | 11 (11.5) | 6 (0.5) | 1 |
| Diarrhea | 42 (27.5) | 27 (28.1) | 15 (26.3) | .85 |
| Pharyngalgia | 29 (19) | 19 (19.8) | 10 (17.5) | .83 |
| Nausea | 9 (5.9) | 2 (2.1) | 7 (12.3) | .01 |
| Fatigue | 78 (51) | 51 (53.1) | 27 (47.4) | .51 |
| Chest pain | 32 (20.9) | 23 (24) | 9 (15.8) | .3 |
| Chest tightness | 45 (29.4) | 33 (34.4) | 12 (21.1) | .1 |
| Palpitation | 53 (34.6) | 37 (38.5) | 16 (28.1) | .29 |
| Nervous system symptoms | ||||
| Any | 119 (77.8) | 71 (74.0) | 48 (84.2) | .16 |
| CNS | 71 (46.4) | 44 (45.8) | 27 (47.4) | .87 |
| Headache | 48 (31.4) | 33 (34.4) | 15 (26.3) | .37 |
| Dizziness | 18 (11.8) | 12 (12.5) | 6 (10.5) | .8 |
| PNS | 106 (69.3) | 61 (63.5) | 45 (78.9) | .05 |
| Impaired taste and smell | 28 (18.3) | 16 (16.7) | 12 (21.1) | .52 |
| Impaired vision | 5 (3.3) | 0 (0) | 5 (8.8) | .01 |
| Nerve pain | 86 (56.2) | 54 (56.3) | 32 (56.1) | 1 |
| Arthralgia | 6 (3.9) | 3 (3.1) | 3 (5.3) | .67 |
| Tingling and numbness | 17 (11.1) | 4 (4.2) | 13 (22.8) | 8.0 × 10−4 |
| Excessive sweating | 41 (26.8) | 28 (29.2) | 13 (22.8) | .45 |
| Muscle weakness | 10 (6.5) | 4 (4.2) | 6 (10.5) | .18 |
| Disease duration † | ||||
| 0‐1 week | 9 (5.9) | 5 (5.2) | 4 (7) | .73 |
| 1–2 weeks | 34 (22.2) | 25 (26) | 9 (15.8) | .16 |
| 2–3 weeks | 44 (28.8) | 39 (40.6) | 5 (8.8) | 1.56 × 10−5 |
| 3–4 weeks | 24 (15.7) | 13 (13.5) | 11 (19.3) | .36 |
| 4–8 weeks | 25 (16.3) | 14 (14.6) | 11 (19.3) | .5 |
| >8 weeks | 17 (11.1) | 0 (0) | 17 (29.8) | 9.06 × 10−9 |
| IgM/IgG serology ‡ | ||||
| No. of patients | 77 | 49 | 28 | N.A. |
| IgM (−) IgG (+) | 31 (40.3) | 27 (55.1) | 4 (14.3) | 5.91 × 10−4 |
| IgM (+) IgG (+) | 15 (19.5) | 10 (20.4) | 5 (17.9) | 1 |
| IgM (+) IgG (−) | 10 (13) | 2 (4.1) | 8 (28.6) | .004 |
| IgM (−) IgG (−) | 21 (27.3) | 10 (20.4) | 11 (39.3) | .11 |
Abbreviations: CNS, central nervous system; PNS, peripheral nervous system.
*
CT findings of viral pneumonia such as ground‐glass opacities and consolidation.
†
Disease duration indicates the time from onset of the symptoms until the symptoms disappeared.
‡
IgM/IgG serological tests were performed 7–8 weeks post disease onset using colloidal gold antibody test kit.